Sonnet BioTherapeutics is set to merge with Hyperliquid Strategies in an ambitious deal valued at 888 million. This merger is expected to result in Hyperliquid Strategies holding 12.6 million HYPE tokens alongside 305 million in cash at the deal’s closing. This significant move illustrates a growing trend of traditional companies entering the cryptocurrency realm. As the merger unfolds, market observers will closely analyze how this partnership will influence Hyperliquid’s strategies and its position in the competitive crypto market. Expectations are high for innovation and growth stemming from this union.